Our peptides are commonly used in research involving: All products are intended for research use only and are not for human or animal consumption, therapeutic use, or clinical application
Tirzepatide is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes, working as a dual GLP-1/GIP receptor agonist that targets both the GLP-1 and GIP receptors instead of GLP-1 alone, which enhances fat metabolism and insulin sensitivity beyond a single-receptor peptide
Clinics generally advise against starting treatment for anyone who: Is pregnant Has a personal or family history of thyroid cancer Has a history of multiple endocrine neoplasia (MEN) syndrome BMI and health history serve as a useful starting point for this evaluation, not an absolute cutoff, since metabolism and overall wellness also weigh into a provider's decision
Short-Term Changes (2026) Additional Category 2 Designations : The FDA continues reviewing peptides for potential Category 2 addition
Pairs well with Epitalon for a multi-pathway anti-aging approach
Despite years of safe compounding, established protocols, and satisfied patients, Category 2 designation meant immediate cessation